Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 April 2021, including: possible new life for Tecfidera; activist investors and GSK; a new mRNA vaccine in Europe; diversity in clinical trials; and a look at last year’s drug launches amid the pandemic.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen" - Scrip, 19 Apr, 2021.)
(Also see "Twitchy Times At GSK As Activist Investor Takes Big Stake" - Scrip, 16 Apr, 2021.)
(Also see "CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach" - Scrip, 16 Apr, 2021.)
(Also see "#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity" - Scrip, 16 Apr, 2021.)
(Also see "Worldwide Novel Drug Launches Soared Amid Pandemic" - Scrip, 19 Apr, 2021.)